Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing

BACKGROUND & AIMS: With the introduction of DAA’s, the majority of treated chronic hepatitis C patients (CHC) achieve a viral cure. The exact mechanisms by which the virus is cleared after successful therapy, is still unknown. The aim was to assess the role of the immune system and miRNA levels...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Ree, Meike H., Stelma, Femke, Willemse, Sophie B., Brown, Anthony, Swadling, Leo, van der Valk, Marc, Sinnige, Marjan J., van Nuenen, Ad C., de Vree, J. Marleen L., Klenerman, Paul, Barnes, Eleanor, Kootstra, Neeltje A., Reesink, Hendrik W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610787/
https://www.ncbi.nlm.nih.gov/pubmed/28844749
http://dx.doi.org/10.1016/j.antiviral.2017.08.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610787/
https://www.ncbi.nlm.nih.gov/pubmed/28844749
http://dx.doi.org/10.1016/j.antiviral.2017.08.016

Ejemplares similares